Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis

J. Iwamoto, K. Makita, Y. Sato, T. Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Summary: A randomized controlled trial was performed to compare the short-term effects of alendronate (ALN) and ECT on pain and quality of life (QOL) in postmenopausal women with osteoporosis. Back pain and QOL [Short-Form Health Survey (SF-8)] significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. These results suggested that ALN reduced back pain and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain. Introduction: Intramuscular ECT is known to reduce pain via the central nervous system. A multicenter randomized controlled trial was performed to compare the short-term effects of ALN and ECTon pain and QOL in postmenopausal women with osteoporosis. Methods: One hundred and 94 postmenopausal osteoporotic women with back pain (mean age 79.8 years, range 60-96 years) were randomly divided into two groups: the ALN group (35 mg weekly) and the ECT group (intramuscular 20 units a week). The duration of the study was 6 months. The trial was completed in 97 (100%) women of the ALN group and 96 (99.0%) women of the ECT group. Urinarylevels of cross-linked N-terminal telopeptide of type I collagen (NTX), serum alkaline phosphatase (ALP), face scale score (FSS, back pain), and SF-8 (QOL) were monitored. Results: UrinaryNTX levels significantly decreased at 3 months in the ALN group, but not in the ECT group. Serum ALP levels significantly decreased at 6 months in the both groups, with a greater reduction in the ALN group. The FSS and SF-8 significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. Conclusions: ALN suppressed bone turnover, reduced back pain, and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain.

Original languageEnglish
Pages (from-to)2735-2742
Number of pages8
JournalOsteoporosis International
Volume22
Issue number10
DOIs
Publication statusPublished - 2011 Oct

Fingerprint

Alendronate
Osteoporosis
Back Pain
Quality of Life
Pain
Alkaline Phosphatase
Randomized Controlled Trials
elcatonin
Bone Remodeling
Health Surveys
Serum
Central Nervous System

Keywords

  • Alendronate
  • Back pain
  • Elcatonin
  • Osteoporosis
  • Postmenopausal women

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. / Iwamoto, J.; Makita, K.; Sato, Y.; Takeda, T.; Matsumoto, Hideo.

In: Osteoporosis International, Vol. 22, No. 10, 10.2011, p. 2735-2742.

Research output: Contribution to journalArticle

Iwamoto, J. ; Makita, K. ; Sato, Y. ; Takeda, T. ; Matsumoto, Hideo. / Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. In: Osteoporosis International. 2011 ; Vol. 22, No. 10. pp. 2735-2742.
@article{4795098a31a34d778196af8bc4ddf5fb,
title = "Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis",
abstract = "Summary: A randomized controlled trial was performed to compare the short-term effects of alendronate (ALN) and ECT on pain and quality of life (QOL) in postmenopausal women with osteoporosis. Back pain and QOL [Short-Form Health Survey (SF-8)] significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. These results suggested that ALN reduced back pain and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain. Introduction: Intramuscular ECT is known to reduce pain via the central nervous system. A multicenter randomized controlled trial was performed to compare the short-term effects of ALN and ECTon pain and QOL in postmenopausal women with osteoporosis. Methods: One hundred and 94 postmenopausal osteoporotic women with back pain (mean age 79.8 years, range 60-96 years) were randomly divided into two groups: the ALN group (35 mg weekly) and the ECT group (intramuscular 20 units a week). The duration of the study was 6 months. The trial was completed in 97 (100{\%}) women of the ALN group and 96 (99.0{\%}) women of the ECT group. Urinarylevels of cross-linked N-terminal telopeptide of type I collagen (NTX), serum alkaline phosphatase (ALP), face scale score (FSS, back pain), and SF-8 (QOL) were monitored. Results: UrinaryNTX levels significantly decreased at 3 months in the ALN group, but not in the ECT group. Serum ALP levels significantly decreased at 6 months in the both groups, with a greater reduction in the ALN group. The FSS and SF-8 significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. Conclusions: ALN suppressed bone turnover, reduced back pain, and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain.",
keywords = "Alendronate, Back pain, Elcatonin, Osteoporosis, Postmenopausal women",
author = "J. Iwamoto and K. Makita and Y. Sato and T. Takeda and Hideo Matsumoto",
year = "2011",
month = "10",
doi = "10.1007/s00198-010-1495-8",
language = "English",
volume = "22",
pages = "2735--2742",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "10",

}

TY - JOUR

T1 - Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis

AU - Iwamoto, J.

AU - Makita, K.

AU - Sato, Y.

AU - Takeda, T.

AU - Matsumoto, Hideo

PY - 2011/10

Y1 - 2011/10

N2 - Summary: A randomized controlled trial was performed to compare the short-term effects of alendronate (ALN) and ECT on pain and quality of life (QOL) in postmenopausal women with osteoporosis. Back pain and QOL [Short-Form Health Survey (SF-8)] significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. These results suggested that ALN reduced back pain and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain. Introduction: Intramuscular ECT is known to reduce pain via the central nervous system. A multicenter randomized controlled trial was performed to compare the short-term effects of ALN and ECTon pain and QOL in postmenopausal women with osteoporosis. Methods: One hundred and 94 postmenopausal osteoporotic women with back pain (mean age 79.8 years, range 60-96 years) were randomly divided into two groups: the ALN group (35 mg weekly) and the ECT group (intramuscular 20 units a week). The duration of the study was 6 months. The trial was completed in 97 (100%) women of the ALN group and 96 (99.0%) women of the ECT group. Urinarylevels of cross-linked N-terminal telopeptide of type I collagen (NTX), serum alkaline phosphatase (ALP), face scale score (FSS, back pain), and SF-8 (QOL) were monitored. Results: UrinaryNTX levels significantly decreased at 3 months in the ALN group, but not in the ECT group. Serum ALP levels significantly decreased at 6 months in the both groups, with a greater reduction in the ALN group. The FSS and SF-8 significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. Conclusions: ALN suppressed bone turnover, reduced back pain, and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain.

AB - Summary: A randomized controlled trial was performed to compare the short-term effects of alendronate (ALN) and ECT on pain and quality of life (QOL) in postmenopausal women with osteoporosis. Back pain and QOL [Short-Form Health Survey (SF-8)] significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. These results suggested that ALN reduced back pain and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain. Introduction: Intramuscular ECT is known to reduce pain via the central nervous system. A multicenter randomized controlled trial was performed to compare the short-term effects of ALN and ECTon pain and QOL in postmenopausal women with osteoporosis. Methods: One hundred and 94 postmenopausal osteoporotic women with back pain (mean age 79.8 years, range 60-96 years) were randomly divided into two groups: the ALN group (35 mg weekly) and the ECT group (intramuscular 20 units a week). The duration of the study was 6 months. The trial was completed in 97 (100%) women of the ALN group and 96 (99.0%) women of the ECT group. Urinarylevels of cross-linked N-terminal telopeptide of type I collagen (NTX), serum alkaline phosphatase (ALP), face scale score (FSS, back pain), and SF-8 (QOL) were monitored. Results: UrinaryNTX levels significantly decreased at 3 months in the ALN group, but not in the ECT group. Serum ALP levels significantly decreased at 6 months in the both groups, with a greater reduction in the ALN group. The FSS and SF-8 significantly improved at 1, 3, and 6 months in both groups, with greater improvements in the ALN group than in the ECT group. Conclusions: ALN suppressed bone turnover, reduced back pain, and improved QOL more markedly than ECT in postmenopausal osteoporotic women with back pain.

KW - Alendronate

KW - Back pain

KW - Elcatonin

KW - Osteoporosis

KW - Postmenopausal women

UR - http://www.scopus.com/inward/record.url?scp=80755143291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755143291&partnerID=8YFLogxK

U2 - 10.1007/s00198-010-1495-8

DO - 10.1007/s00198-010-1495-8

M3 - Article

VL - 22

SP - 2735

EP - 2742

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 10

ER -